Health Press Release – Monthly Newsletter January 2011

IDEV Technologies Announces First U.S. Procedure With SUPERA VERITAS(TM) Transhepatic Biliary System

Commercial Launch of Stent Delivery System Planned for Early 2011
WEBSTER, Texas, November 30, 2010 – IDEV Technologies, Incorporated (IDEV), an innovative leader in the
development and commercialization of minimally invasive medical technologies,
today announced the first procedure in the United States utilizing the SUPERA
VERITAS(TM) Transhepatic Biliary System, which was recently cleared to market
by the U.S. Food …. Source article on Gaea Times at  : IDEV Technologies Announces First U.S. Procedure With SUPERA VERITAS(TM) Transhepatic Biliary System.

UK’s Indoor Air is Under Attack by Parliament

SURREY, England, November 30, 2010 – The Parliamentary Office of Science and Technology (POST) reports that
poor indoor air can cause ill health and disease, and that "no single
government department has ownership of this issue." Simultaneously, Asthma UK
unveiled research that named indoor triggers that cause asthma in the first
place.

These two significant …. Source  : Gaea News Network.

Life Healthcare Upbeat After Robust Maiden Results

JOHANNESBURG, November 30, 2010 – Life Healthcare Group Holdings Limited ("Life Healthcare" or the
"Group"), a leading provider of private healthcare services in southern
Africa, today released its maiden set of annual financial results for the
year ended 30 September 2010 since listing on the JSE on 10 June.

Highlights of the results include:

… Original source on Gaea Times at : Life Healthcare Upbeat After Robust Maiden Results.

Medivation and Astellas Complete Enrollment in Phase 3 AFFIRM trial of MDV3100 in Advanced Prostate Cancer

SAN FRANCISCO and TOKYO, November 30, 2010 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. today announced
that patient enrollment was completed on November 15, 2010 in the Phase 3
AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral
androgen receptor antagonist, in patients with advanced prostate cancer who
have previously been treated with chemotherapy.

… Read more »»».

HCL Technologies Enters Into Multi Year end-to-end IT Infrastructure Management Engagement With Purdue Pharma L.P.

NOIDA, India, November 30, 2010 – HCL Technologies Ltd. (HCL), a leading global IT services
provider, today announced that it has signed a multi year end-to-end IT
Infrastructure Management engagement with pharmaceutical company Purdue
Pharma L.P. The scope of this engagement covers management of two data
centers and all remote locations of the client in the U.S.

[..] Read the original article: here.

Gen-Probe Launches PANTHER(TM) System, Fully Automated and Integrated Molecular Testing Instrument, in Europe

System Offers Revolutionary Productivity and Flexibility for Laboratories
SAN DIEGO, November 30, 2010 – Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company's
PANTHER(TM) system, a fully automated and integrated molecular testing system
designed with the flexibility to handle a wide range of testing needs, has
been CE-marked and is available for sale in Europe.

…. Original article on Gaea Times at  : Gen-Probe Launches PANTHER(TM) System, Fully Automated and Integrated Molecular Testing Instrument, in Europe.

Bring in Group B Strep Testing for all Women to Save Money and Lives, Urges Group B Strep Support

HAYWARDS HEATH, England, December 1, 2010 – Group B Strep Support (GBSS), the charity for the UK's biggest cause of
life-threatening infection newborn babies, is urging the Government to make
sensitive testing for group B Streptococcus (GBS) available for all pregnant
women, as recent research shows this would save money as well as tiny babies'
lives.

… Original source on Gaea Times at : Bring in Group B Strep Testing for all Women to Save Money and Lives, Urges Group B Strep Support.

SEEK: PepTcell Changes Name due to New Focus and Success

LONDON, December 1, 2010 – PepTcell, a leading UK privately-owned drug-discovery group, today
announced it is changing its name to SEEK.

Gregory Stoloff, Chief Executive Officer, explains: "SEEK has
a significant number of potential blockbuster assets in different legal
entities and we wanted to give them a common identity and purpose. Announcing
a simple and …. Source article  : SEEK: PepTcell Changes Name due to New Focus and Success.

Shire Reports Positive Efficacy and Safety Results From FAST-3 Study of FIRAZYR(R) (icatibant) for Acute Attacks of Hereditary Angioedema

DUBLIN, December 1, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today announced topline results from FAST-3 (For
Angioedema Subcutaneous Treatment), the largest of the Phase III trials
studying the use of FIRAZYR(R) (icatibant) for treatment of acute attacks of
hereditary angioedema (HAE).

The study showed that patients receiving treatment …. Read the original article  : here.

Elsevier Launches Innovative Online Radiology Board Review Product

New Case Reviews Online Series Mimics Format of Board Exams and Offers Interactive Self-Assessment Environment for Radiology Professionals

PHILADELPHIA, December 1, 2010 – Elsevier (www.elsevier.com/), the leading publisher of scientific,
technical and medical information products and services, today announced the
availability of Case Reviews Online, an online edition of Case Reviews print
series offering radiology professionals self-assessment preparation … Read more »».

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation

More Than 21,000 Patients Enrolled in the Largest Clinical Study With a Factor Xa Inhibitor

LONDON, December 1, 2010 – Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has
successfully completed patient enrollment for its phase III ENGAGE AF-TIMI 48
clinical study of edoxaban, a direct, specific, oral Factor Xa inhibitor that
is being investigated in … Read : Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation.

Experts Emphasize That Beta-Carotene is Indispensable as a Safe Source of Vitamin A

JENA, Germany, December 1, 2010 – The intake of preformed vitamin A from animal products is not
sufficient in parts of the population in Europe, the U.S. and Asia. The
vitamin A precursor beta-carotene therefore has an important function in
providing for an adequate supply of total vitamin A, international carotenoid
experts state in a recently published consensus …. Source article on Gaea Times at  : Experts Emphasize That Beta-Carotene is Indispensable as a Safe Source of Vitamin A.

Janssen Pharmaceutica N.V. Announces Collaboration to Develop Diagnostic Biosignatures for Pre-Symptomatic Identification of Alzheimer’s Disease

BEERSE, Belgium, December 1, 2010 – Janssen Pharmaceutica N.V., (Janssen) today announced a research
agreement to collaborate with GE Healthcare to develop non-invasive or
minimally invasive diagnostic biosignatures to detect Alzheimer's disease
prior to the onset of clinical symptoms. Pre-symptomatic biosignatures will
allow earlier diagnosis of the disease and may enable significantly earlier
intervention in Alzheimer's disease.

… Read the original article on Gaea Times at : Janssen Pharmaceutica N.V. Announces Collaboration to Develop Diagnostic Biosignatures for Pre-Symptomatic Identification of Alzheimer's Disease.

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation

More Than 21,000 Patients Enrolled in the Largest Clinical Study with a Factor Xa Inhibitor

TOKYO, December 1, 2010 – Daiichi Sankyo Company, Limited (TSE: 4568), announced today
that it has successfully completed patient enrollment for its phase III
ENGAGE AF-TIMI 48 clinical study of edoxaban, a direct, specific, oral Factor
Xa inhibitor that is being investigated in … Read : Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation.

MarketsandMarkets: U.S. Biopharmaceuticals Market Worth $144 Billion by 2016

DALLAS, December 2, 2010 – BIOPHARMA analyzes the U.S. Biopharmaceuticals Market and its growth
factors, with special emphasis on the top companies in the field and their
product pipeline. The report also analyses the current trends and focus of
the U.S. biopharmaceutical market and the challenges faced by the industry.
It also provides profiles of the major companies …. Source article on Gaea Times at  : MarketsandMarkets: U.S. Biopharmaceuticals Market Worth $144 Billion by 2016.

SUTENT(R) Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET)

First Targeted Therapy Approved for the Treatment of Pancreatic NET in Europe

NEW YORK, December 2, 2010 – Pfizer Inc. (NYSE: PFE) announced today that the European Commission has
approved SUTENT(R) (sunitinib malate) for the treatment of unresectable or
metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with
disease progression in adults. Experience with SUTENT as initial treatment is
limited in … Read the original article on Gaea Times at : SUTENT(R) Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET).

Nordion Signs Letter of Intent to Divest MDS Nordion S.A.

Best Medical International Inc. Prospective Buyer of Nordion Belgium Operations

OTTAWA, December 2, 2010 – Nordion Inc. (TSX: NDN; NYSE: NDZ), a leading provider of products and
services to the global health science market, today announced it has signed a
non-binding letter of agreement with Best Medical International Inc. for the
divestiture of MDS Nordion S.A.
…. Original source  : Nordion Signs Letter of Intent to Divest MDS Nordion S.A..

TFI Extends Pharma Team After New Account Wins

LONDON, December 2, 2010 – TFI Group, one of the UK's leading event management agencies, has seen
its pharmaceutical division grow following a number of high-profile account
wins.

The account wins are the Japanese pharmaceutical company Daiichi Sankyo
Europe, to handle their portfolio of events across Europe, and an
international biotechnology company.
… Read more : TFI Extends Pharma Team After New Account Wins.

Data on Over 50,000 UK Adults Shows Fresh, Raw Nuts and Seeds Help With Energy Levels and Overall Health

Need More Energy? Break out the Nutcracker This Christmas
LONDON, December 2, 2010 – Online nutrition profiling firm MyNutrition.co.uk has identified that
fresh, raw nuts and seeds have a significant association with high energy
levels in adults. This is good news during the festive season since fresh
nuts are easy to obtain.

MyNutrition.co.uk looked at … Read more >>.

BMEYE and PULSION Sign Licensing Agreement

BMEYE's Breakthrough Totally Noninvasive Blood Pressure and Cardiac Output Technology Will be Incorporated Into PULSION's Next Generation Patient Monitors

AMSTERDAM, December 2, 2010 – BMEYE B.V., the innovators of a totally noninvasive combined beat-to-beat
blood pressure and cardiac output monitoring system, and PULSION Medical
Systems AG, a leading specialist in minimally invasive critical care and
cardiovascular patient monitoring, …. Source  : Gaea News Network.

New Report Indicates VERILAST(TM) Technology From Smith & Nephew Orthopaedics has Lowest Revision Rate Among all Hip Replacement Materials

Database tracking more than 150,000 hip implants shows ceramicized metal devices achieve highest survivorship rate five years after surgery

MEMPHIS, Tennessee, December 2, 2010 – A newly released patient registry reports that hip replacement implants
made from ceramicized metal heads which articulate against polyethylene lined
cups have been shown to have superior survivorship compared to implants made
from … Read this article on Gaea Times at : New Report Indicates VERILAST(TM) Technology From Smith & Nephew Orthopaedics has Lowest Revision Rate Among all Hip Replacement Materials.

The Harley Medical Group Sees an Uptake in Surgery Bookings for Christmas

LONDON, December 2, 2010 – The Harley Medical Group is reporting a 35% surge in patients booking in
for surgical procedures YOY as an early present for themselves, the month
before Christmas.

Many patients are taking extended Christmas holidays to ensure a full
recovery is made before they return to work in the New …. Source article  : The Harley Medical Group Sees an Uptake in Surgery Bookings for Christmas.

‘Include Veterinary Care in Christmas Plans,’ Advises the Royal College of Veterinary Surgeons

LONDON, December 3, 2010 – If you own a pet, remember to check your vet's opening hours in the run
up to Christmas, advises the Royal College of Veterinary Surgeons (RCVS), the
regulatory body for veterinary surgeons. In particular, pet owners should
make sure they know what the arrangements are for emergencies when the
practice is closed.

… Read the original article on Gaea Times at : 'Include Veterinary Care in Christmas Plans,' Advises the Royal College of Veterinary Surgeons.

INTUNIV(TM) – Shire Files Suit Against Impax and Watson

DUBLIN and PHILADELPHIA, December 3, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announces that its subsidiary Shire LLC has filed
a lawsuit in the U.S. District Court for the Northern District of California
against Impax Laboratories, Inc. ("Impax") and Watson Pharmaceuticals, Inc.,
Watson Laboratories, Inc.-Florida, Watson Pharma, Inc and ANDA, Inc.
(collectively "Watson") … Read this article on Gaea Times at : INTUNIV(TM) – Shire Files Suit Against Impax and Watson.

Chronic Fatigue Syndrome Patients Run First-ever Ad in The Washington Post

Possible New HIV-like Retrovirus in Blood Supply
CORAL GABLES, Florida, December 6, 2010 – In an unprecedented move, chronic fatigue syndrome (CFS) patients
published a half-page ad in The Washington Post today. The ad brings
attention to new, HIV-like retroviruses, including XMRV, which have been
linked to CFS and aggressive prostate cancer, and have been detected in
healthy blood …. Original article on Gaea Times at  : Chronic Fatigue Syndrome Patients Run First-ever Ad in The Washington Post.

Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer

Read Succeeds Jeffrey B. Kindler, who has Retired from the Company
NEW YORK, December 6, 2010 – Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has
elected Ian C. Read, 57, currently head of the Company's global
biopharmaceutical operations, as President, Chief Executive Officer and
Director. Mr. Read succeeds Jeffrey B. Kindler, who has retired …. Source article on Gaea Times at  : Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer.

Steve Newman Appointed Chief Technical Officer for Menicon Co.

Newman Taking on Worldwide Responsibility for Product Planning, Manufacturing and Technology

NAGOYA, Japan, December 7, 2010 – Menicon Co., Ltd. has announced the appointment of Steven Newman as Chief
Technical Officer for the company.
(Photo: www.newscom.com/cgi-bin/prnh/20101206/MM11663)
Newman joined Menicon with the acquisition of ClearLab's Flat Pack
technology from 1-800 Contacts in …. Read the original article  : Steve Newman Appointed Chief Technical Officer for Menicon Co..

Bill & Melinda Gates Foundation Statement on the Launch of New Meningitis Group A Vaccine

OUAGADOUGOU, Burkina Faso, December 6, 2010 – Tachi Yamada, president of the Bill & Melinda Gates Foundation's Global
Health Program, issued the following statement to mark the launch of
MenAfriVac-a new vaccine against Meningitis Group A-in Burkina Faso:

"MenAfriVac is a tremendous success story for the global health
community. It is the first vaccine … Read this article on Gaea Times at : Bill & Melinda Gates Foundation Statement on the Launch of New Meningitis Group A Vaccine.

Optical Express Announces December HD TV Give-away

Win a 46" Samsung Full HD LED TV This Christmas
GLASGOW, Scotland, December 6, 2010 – Each week during December, to celebrate superior vision, everyone who
attends a FREE laser eye surgery consultation at Optical Express will be
automatically entered into a draw to win one of four fantastic 46" Samsung
Full HD LED TVs.

… Read the original article on Gaea Times at : Optical Express Announces December HD TV Give-away.

Follow-Up Results from Study Comparing SPRYCEL(R) (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data[1]

18-Month Data Presented at 52nd Annual Meeting of the American Society of Hematology[1]

PRINCETON, New Jersey and TOKYO, December 6, 2010 – Bristol-Myers Squibb Company (www.bms.com) (NYSE:BMY) and Otsuka
Pharmaceutical Co., Ltd. today announced 18-month follow-up results from the
Phase 3 DASISION study of SPRYCEL(R) (dasatinib) 100 mg once daily vs.
imatinib (400 mg daily) in the first-line …. Read the original article  : here.

Setting the Record Straight on Hot Flushes – as Women Lift Lid on the Menopause

OXFORD, England, December 6, 2010 – A ground-breaking website today lifts the lid on the menopause – and
could save women from suffering alone, misunderstood by unsympathetic
partners and sniggering workmates.

The new section of award-winning www.healthtalkonline.org features
46 women from all walks of life – who reveal "everything you wanted to know
but were …. Original article  : Setting the Record Straight on Hot Flushes – as Women Lift Lid on the Menopause.

Cinryze(R) (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)

DUBAI, United Arab Emirates, December 6, 2010 – ViroPharma Incorporated (Nasdaq: VPHM) today announced data in five
poster presentations relating to Cinryze(R) (C1 esterase inhibitor [human])
at the 2010 International Scientific Conference of the World Allergy
Organization (WAO), December 5 through 8 in Dubai, UAE.

This is the first international presentation of these data, …. Source article on Gaea Times at  : Cinryze(R) (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO).

ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program

EXTON, Pennsylvania and WEYBRIDGE, England, December 6, 2010 – ViroPharma Incorporated (Nasdaq: VPHM) and Idis, the global leader in
developing long-term strategic solutions to therapeutic access, today
announced that the two companies have partnered to facilitate access to
certain ViroPharma products through a named patient program (NPP).
ViroPharma's NPP, developed and managed by Idis, will allow international
healthcare professionals … Read : ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program.

CIC Chooses MGS as Exclusive Reseller to Achieve eSignature Growth Objective in the Middle East

REDWOOD SHORES, California, December 6, 2010 – (OTC Bulletin Board: CICI) Communication Intelligence Corporation ("CIC")
the leading supplier of electronic signature solutions for business process
automation in the financial industry and the recognized leader in biometric
signature verification announced today the appointment of MGS, certified
reseller partner of OpenText (www.opentext.com/2/global.htm) and a
leading provider of IT consulting and implementation … Read more >>>.

Experts Reach Agreement on the Most Important Attributes of Combination Therapies for Asthma

The Agreement Will Provide Physicians With Much Needed Guidance for Choosing the Best Combination Therapy for Their Asthma Patients

CAMBRIDGE, England, December 6, 2010 – Data presented today at the World Allergy
Organization (WAO) International Conference have shown that: clinical
efficacy, safety, tolerability and speed of onset of a long-acting
Beta2-agonist (LABA), potency of an inhaled corticosteroid (ICS), …. Source article  : Experts Reach Agreement on the Most Important Attributes of Combination Therapies for Asthma.

VELCADE(R) (bortezomib) Administered Subcutaneously Shows Comparable Response Rates and Safety Profile Compared to Intravenous Administration in the Treatment of Relapsed Multiple Myeloma

Data From Another Study Demonstrating the Efficacy of VELCADE Maintenance Monotherapy and Improvements in Quality of Life Presented at the 52nd American Society of Hematology Annual Meeting

BEERSE, Belgium, December 6, 2010 – Janssen Pharmaceutical Companies today announced the results from data
presented at the 52nd American Society for Hematology (ASH) Annual Meeting in
Orlando, which demonstrated … Read : VELCADE(R) (bortezomib) Administered Subcutaneously Shows Comparable Response Rates and Safety Profile Compared to Intravenous Administration in the Treatment of Relapsed Multiple Myeloma.

Torchmark Corporation Declares Dividend

MCKINNEY, Texas, December 6, 2010 – Torchmark Corporation (NYSE: TMK) announced that its Board of Directors
has declared a quarterly dividend of $.16 per share on all of the outstanding
common stock of the Company held of record as of the close of business of the
Company's transfer agent on January 6, 2011. The dividend will be … Original article on : Torchmark Corporation Declares Dividend.

Global Dental Devices and Consumables Market (2010 – 2015) Now Available at ReportsnReports

DALLAS, December 7, 2010 – ReportsnReports announces it will carry Global Dental Devices and
Consumables Market (2010 – 2015) Research Report in its store.

Browse the complete Report on:
www.reportsnreports.com/reports/41940-global-dental-devices-and-
consumables-market-2010-2015.html
(Due to the length of this URL, it may be necessary to copy and paste
this hyperlink into your Internet browser's … Original article on : Global Dental Devices and Consumables Market (2010 – 2015) Now Available at ReportsnReports.

Global Dental Implants Market Research Report now Available ReportsnReports

ReportsnReports Announces it will Carry Global Dental Implants Market Research Report in its Store.

DALLAS, December 7, 2010 – Browse the complete Report on:
www.reportsnreports.com/reports/26644-global-dental-implants-market-20
10-2015.html
(Due to the length of this URL, it may be necessary to copy and paste
this hyperlink into your Internet browser's URL address field. Remove the
space if one exists.)
… Original article on : Global Dental Implants Market Research Report now Available ReportsnReports.

Accumetrics Closes 2010 With Positive Outlook

Pharmaceutical collaboration, GRAVITAS clinical trial results, distribution agreements, and capital financing position Company for continued growth in 2011

SAN DIEGO, December 7, 2010 – Accumetrics, Inc., a privately-held developer and marketer of the
VerifyNow(R) System, the first rapid and easy-to-use point-of-care system for
measuring platelet reactivity to multiple antiplatelet agents, closes 2010
with continued positive medical community and …. Source article  : Accumetrics Closes 2010 With Positive Outlook.

New NIH Guidelines Advocate ImmunoCAP Blood Test to Improve Diagnosis of Food Allergy

UPPSALA, Sweden, December 8, 2010 – New guidelines on diagnosis and management of food allergy issued by the
National Institute of Allergy and Infectious Diseases a part of NIH, supports
a broader use of blood test to improve current clinical practice.
Phadia's ImmunoCAP is recognized for its superior predictive values compared
to other systems. It provides precise, quantitative …. Original article  : New NIH Guidelines Advocate ImmunoCAP Blood Test to Improve Diagnosis of Food Allergy.

The Binding Site Appoints Charles de Rohan as Chief Executive Officer

BIRMINGHAM, England, December 8, 2010 – The Binding Site Corporation Limited ("Binding Site" or "the
Company"), a privately-owned specialist U.K. diagnostics company, today
announces the appointment of Charles de Rohan as Chief Executive Officer.

Charles de Rohan has worked in the diagnostic industry for
more than 17 years and brings significant experience to the … Read the original article on Gaea Times at : The Binding Site Appoints Charles de Rohan as Chief Executive Officer.

Informex and CMS Pharma Present Inaugural CEO Summit of Pharma Manufacturing

First annual CEO Summit will provide forum for senior industry executives to discuss business strategies and trends in Custom Manufacturing of pharmaceutical ingredients

PRINCETON, New Jersey and INGELHEIM, Germany, December 8, 2010 – Informex, the leading meeting place for buyers and sellers of high-value
chemistry for a broad range of applications, and CMS Pharma, the trusted … Read more : Informex and CMS Pharma Present Inaugural CEO Summit of Pharma Manufacturing.

AVESTHAGEN’s First Biosimilar Molecule AVDESP(TM) Completes Clinical Batch Manufacturing in Malaysia, to Move to Clinical Trials

BANGALORE, India, December 8, 2010 – AVESTHAGEN LIMITED, a leading knowledge based life sciences
company pioneering the convergence between Food, Pharma and Population
Genetics, today announced the completion of manufacturing of the clinical
grade material of its first biosimilar molecule- AVDESP(TM) (biosimilar to
Darbepoetin alfa), which will now be moving into Clinical Trials. Inno
Biologics, Malaysia's biopharma CMO has … Original source on Gaea Times at : AVESTHAGEN's First Biosimilar Molecule AVDESP(TM) Completes Clinical Batch Manufacturing in Malaysia, to Move to Clinical Trials.

Elsevier Enables its e-Books to Read Aloud, Increasing Access for People With Print Disabilities

Text-to-Speech Option Enabled for All Elsevier ePub Book Titles
AMSTERDAM, December 8, 2010 – Elsevier, the world-leading publisher of scientific, technical and
medical information products and solutions, announced today that it has
enabled the text-to-speech option on all of its ePub book titles. The
text-to-speech function enables an e-book to read aloud. This will facilitate
access by readers who … Original article on : Elsevier Enables its e-Books to Read Aloud, Increasing Access for People With Print Disabilities.

/C O R R E C T I O N – Phadia/

UPPSALA, Sweden, December 8, 2010 – In the news release, "New NIH Guidelines Advocate ImmunoCAP Blood Test to
Improve Diagnosis of Food Allergy" issued on 8 Dec 2010 10:56 GMT, by
Phadia over PR Newswire, please note that the link after the first paragraph
has been updated to:
(Logo: www.newscom.com/cgi-bin/prnh/20101208/425503 )
Complete, updated release follows:

New …. Original source  : /C O R R E C T I O N — Phadia/.

NNIT Buys ChannelCRM to Better Service Pharma Businesses

NNIT Buys ChannelCRM – a Specialised Vendor of CRM and Industry Specific xRM Solutions

COPENHAGEN, December 8, 2010 – NNIT has bought Danish software house ChannelCRM in order to further
develop our Customer Relationship Management (CRM) offerings devoted to the
pharmaceutical industry.
(Logo: www.newscom.com/cgi-bin/prnh/20101005/412747 )
The pharmaceutical industry demands both …. Source article  : NNIT Buys ChannelCRM to Better Service Pharma Businesses.

Zealand Pharma Receives Milestone Payment From Helsinn Healthcare

ZP1846, a Novel GLP-2 Agonist, Continues to Advance in Clinical Development Under Licensing Agreement

COPENHAGEN, December 9, 2010 – Zealand Pharma A/S (NASDAQ OMX: ZEAL) ("Zealand Pharma" or
"the Company"), a biopharmaceutical company dedicated to the discovery and
development of innovative peptide drugs that recently listed on NASDAQ OMX,
today announces the receipt of a EUR 500,000 (DKK … Original source on Gaea Times at : Zealand Pharma Receives Milestone Payment From Helsinn Healthcare.

Circle Secures GBP50M Funding for Second New-Build Hospital

LONDON, December 9, 2010 – Circle, the employee-owned partnership of clinicians, has today secured
GBP50m to fund its second new-build hospital – CircleReading.

In a deal that signals a breakthrough in the UK development
finance freeze, the site for the hospital has been purchased by the real
estate investment arm for BP's pension fund, …. Original article on Gaea Times at  : Circle Secures GBP50M Funding for Second New-Build Hospital.

Elsevier Offers Scientific Book Content Through Google eBooks

Important Step in Increasing Access to Broader Audience
NEW YORK, December 9, 2010 – Elsevier, the world-leading publisher of scientific, technical and
medical information products and services, announced today that it is
participating in the recently launched Google eBooks store by including a
large selection of Elsevier's eBook titles. Elsevier regards Google eBooks as
a valuable new distribution channel … Read more : Elsevier Offers Scientific Book Content Through Google eBooks.

Transformation at Top of Agenda for CPMRC’s Annual Conference in Jan. 2011

Video Interview of Dee Hock, Founder of VISA, Adds to Overall Conference Focus on Transformational Leadership in Healthcare

GRAND RAPIDS, Michigan, December 9, 2010 – The 19th International Conference (Jan. 19-22, 2011)
(www.cpmrc.com/consortium/conference/) of the CPM Resource Center
(www.cpmrc.com/) (CPMRC), an Elsevier (www.elsevier.com/)
company and leader in assisting healthcare organizations improve practice at
the point of care, will focus …. Source article  : Transformation at Top of Agenda for CPMRC's Annual Conference in Jan. 2011.

Merck Serono and San Raffaele Scientific Institute to Collaborate on Research in Neurodegenerative Diseases

GENEVA, December 13, 2010 – Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today
announced a strategic collaboration with the Institute of Experimental
Neurology (INSpe) and the Department of Neurology of the San Raffaele
Scientific Institute (Milan, Italy) to advance clinical research projects in
multiple sclerosis and neurodegenerative diseases.

This collaboration follows previous agreements, …. Source  : Gaea News Network.

Ocean Nutrition Canada Limited Announces Strategic Alliance with Wilmar International Limited – the World’s Largest Omega-3 EPA/DHA Food Company

Makers of Arawana Brand Cooking oil Bring a Healthier Product to Their Consumers

DARTMOUTH, Canada, December 14, 2010 – Ocean Nutrition Canada Limited (ONC), the
world's largest Omega-3 EPA/DHA solutions provider, and supplier of MEG-3(R)
brand Omega-3 EPA/DHA (eicosapentaenoic acid/docosahexaenoic acid)
ingredients, is pleased to announce that it has entered into an exclusive
long term strategic agreement with Wilmar … Original source on Gaea Times at : Ocean Nutrition Canada Limited Announces Strategic Alliance with Wilmar International Limited – the World's Largest Omega-3 EPA/DHA Food Company.

SulAmerica Enters into Contract to Acquire Dental PLAN

The acquisition will increase dental care portfolio by more than 30%
SAO PAULO, December 14, 2010 – SulAmerica (BM&FBovespa: SULA11) announced today the signing of a share
purchase agreement for the acquisition of Dental PLAN Ltda., one of the major
dental care providers in the North and Northeast regions of Brazil, which has
also shown a significant growth …. Source article on Gaea Times at  : SulAmerica Enters into Contract to Acquire Dental PLAN.

3D Keyhole Surgery at the Forefront of Cutting-edge Research

GUILDFORD, England, December 14, 2010 – Doctors will shortly be performing the world's first remote 3D keyhole
surgery during a symposium at the University of Surrey. Keyhole surgery -
where doctors operate on organs through a tiny incision – reduces the length
of hospital stays and post-operative complications. This also means that
patients experience less scarring and pain. … Read more >>.

Italy’s National Agency for Regional Health Services (Agenas) Names Zimmer(R) NexGen(R) LPS Knee the Most Cost-Effective Total Knee Replacement Implant

WINTERTHUR, Switzerland, December 14, 2010 – Zimmer Holdings, Inc. (NYSE: ZMH; SIX: ZMH), a leader in musculoskeletal
care, today announced that the Zimmer NexGen LPS knee was ranked the most
cost-effective multiradius design total knee replacement implant in Italy in
a recent health technology assessment by Italy's National Agency for Regional
Health Services.(1)

The assessment … Read the original article on Gaea Times at : Italy's National Agency for Regional Health Services (Agenas) Names Zimmer(R) NexGen(R) LPS Knee the Most Cost-Effective Total Knee Replacement Implant.

Cell Biosciences Announces US Patent Issuance

SANTA CLARA, California, December 14, 2010 – Cell Biosciences, Inc. today announced the issuance of Patent No.
7,846,676 for "Methods and Devices for Analyte Detection" by the United
States Patent and Trademark Office.

The patent represents a key element of intellectual property related to
NanoPro assay technology. It is one of several within a … Read : Cell Biosciences Announces US Patent Issuance.

Elsevier Launches Executable Paper Grand Challenge

Contest Created to Improve the way Scientific Information is Communicated and Used

NEW YORK, December 14, 2010 – Elsevier, a leading global publisher of scientific, technical and medical
information, announced today that it has launched a new competition that
invites scientists to improve how data intensive research is represented in a
scholarly journal article. The Elsevier Executable Paper …. Original source  : Elsevier Launches Executable Paper Grand Challenge.

Amira Pharmaceuticals to Present Preclinical, Clinical Data from DP2 Receptor Antagonist Program at Pacifichem 2010

SAN DIEGO, December 14, 2010 – Amira Pharmaceuticals, Inc. announced today that it will present
preclinical and clinical data from its DP2 receptor antagonist program on
December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from
Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D.,
in a presentation titled "Discovery and optimization of a …. Read the original article  : Amira Pharmaceuticals to Present Preclinical, Clinical Data from DP2 Receptor Antagonist Program at Pacifichem 2010.

The First Biotechnology Company That Measures Telomeres

Dr. Mar??a Blasco, the Bot??n Foundation and Matlin Associates Establish Life Length, S.L.

MADRID, December 15, 2010 – Life Length, S.L. is a new biotechnology company set up to
measure the length of telomeres which form caps at the end of chromosomes and
that have a fundamental role in avoiding the break down and the aging of
cells … Read more »»».

Agendia Publishes Compelling First Independent Validation Study of Colon Cancer Recurrence Test “ColoPrint” in Journal of Clinical Oncology

Second Independent Validation Study of ColoPrint Selected for Oral Presentation and Press Conference at ASCO GI in January 2011

IRVINE, California and AMSTERDAM, December 15, 2010 – Agendia, a world leader in molecular cancer diagnostics,
announced today that together with principal investigators from Spain, the
UK, and the Netherlands, it has published the first independent validation
study of …. Original article  : Agendia Publishes Compelling First Independent Validation Study of Colon Cancer Recurrence Test "ColoPrint" in Journal of Clinical Oncology.

Elsevier Bringing Together Thought Leaders and Experts for New International Conference in Bionic Engineering

AMSTERDAM, December 15, 2010 – The International Bionic Engineering Conference 2011 (
www.bionicengineeringconference.com/index.html) organised by Elsevier,
the leading publisher of scientific, technical and medical information
products and services, aims to bridge the gap between academic research and
industrial development in a field that is rapidly growing and gaining
recognition across many disciplines.

Intended as a common …. Source  : Elsevier Bringing Together Thought Leaders and Experts for New International Conference in Bionic Engineering.

Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor

Potential Utility in Various Cancers
SAN DIEGO, December 15, 2010 – Amira Pharmaceuticals, Inc. announced today that it has successfully
identified a novel pre-clinical candidate for its newest lysophosphatidic
acid (LPA)-related program, autotaxin. Autotaxin is an enzyme upstream from
LPA receptors and has been implicated in a number of diseases including
rheumatoid arthritis, glioblastoma, lung, breast, ovarian and thyroid
cancers.

… Read more : Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor.

Valkee Closes Angel Funding With Esther Dyson and Anssi Vanjoki

HELSINKI, December 15, 2010 – Esther Dyson and Anssi Vanjoki have invested in Valkee as part
of company's EUR 400,000 angel round. Valkee makes the bright light headset
to treat and prevent seasonal affective disorder and other depression types.
In clinical trials, 9 out of 10 patients have had symptoms relief in four
weeks, using Valkee 8-12 minutes …. Original article on Gaea Times at  : Valkee Closes Angel Funding With Esther Dyson and Anssi Vanjoki.

Topical Market Research Reports by Future Markets Published at MarketPublishers.com

LONDON, December 16, 2010 – Market Publishers Ltd informs that new in-demand market
research reports by Future Markets, Inc (
marketpublishers.com/members/future_markets/info.html) have been added
to its catalogue.

Nanocoatings for the Aerospace Industry. This research presents a
detailed analysis of production methods and coating types, provides
information on market structures, market drivers and revenues. The research
presents detailed …. Source  : Gaea News Network.

New Topical Research Reports by iData Research Published by MarketPublishers.com

LONDON, December 16, 2010 – Market Publishers Ltd informs that new in-demand market research
reports by iData Research
(marketpublishers.com/members/idata_research/info.html) have been
added to its catalogue.

Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology &
Ablation Devices 2011. In 2010, the Asia Pacific markets for cardiac rhythm
management (CRM), electrophysiology and ablation devices were valued at over
$1.4 billion. … Original source on Gaea Times at : New Topical Research Reports by iData Research Published by MarketPublishers.com.

Nice Supports the use of Low-Intensity Pulsed Ultrasound to Accelerate Bone Fracture Healing

Smith & Nephew's EXOGEN(TM) Ultrasound Bone Healing System Acknowledged as Efficacious and Safe Route to Rapid Recovery From Fractures

YORK, England, December 16, 2010 – The National Institute for Health and Clinical Excellence
(NICE) has advised healthcare professionals in the UK that the use of low
intensity pulsed ultrasound (LIPUS) technology represents a safe and
effective treatment option … Read this article on Gaea Times at : Nice Supports the use of Low-Intensity Pulsed Ultrasound to Accelerate Bone Fracture Healing.

Researchers Confirm Omega-3 EPA Required for Antidepressant Benefits

DARTMOUTH, Canada, December 16, 2010 – Researchers at the University of Illinois at Chicago completed a review
of previously published research on antidepressant benefits of Omega-3
essential fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA). The review comprised a meta-analysis of 15 randomized, double-blind,
placebo-controlled studies in patients with depression and results were
presented at the recent annual … Original article on : Researchers Confirm Omega-3 EPA Required for Antidepressant Benefits.

COPAN Files New Patents Following the Development of High Nucleic Acid Yield Flocked Swabs

MURRIETA, California, December 16, 2010 – COPAN has enjoyed widespread use of its flocked swabs line, branded as
FLOQSwabs, in microbiology for the collection and transportation of bacterial
and viral samples.

FLOQSwabs by COPAN have been shown through numerous independent studies
to collect more sample and elute the entire sample thus improving the
detection and … Read more : COPAN Files New Patents Following the Development of High Nucleic Acid Yield Flocked Swabs.

InterMune Announces Positive Opinion for Approval of Esbriet(TM) (Pirfenidone) in European Union

BRISBANE, California, December 17, 2010 – — Esbriet to be the first medicine approved for IPF patients in the EU –

InterMune, Inc. (Nasdaq: ITMN) today announced that the Committee for
Medicinal Products for Human Use (CHMP) of the European Medicines Agency
(EMA) has adopted a positive opinion recommending the granting of a …. Original article  : InterMune Announces Positive Opinion for Approval of Esbriet(TM) (Pirfenidone) in European Union.

InspireMD Celebrates Successful ICI 2010 Meeting; Long-Term Data Validates MGuard as Potentially Important Tool in Modern Acute MI Therapy

Distinguished Panel Chaired by Dr. Martin B. Leon, From Columbia University Medical Center, Discuss Advancement of MGuard

TEL AVIV, Israel, December 17, 2010 – InspireMD, developer of the novel MGuard(TM), a combination of
a coronary stent merged with an embolic protection specifically designed for
Acute MI (AMI) patients, received significant exposure at the ICI,
Innovations in Interventional Cardiology, … Read the original article on Gaea Times at : InspireMD Celebrates Successful ICI 2010 Meeting; Long-Term Data Validates MGuard as Potentially Important Tool in Modern Acute MI Therapy.

InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet(TM) (Pirfenidone) in Europe

BRISBANE, California, December 17, 2010 – — Conference call and webcast today at 8:30 a.m. EST to discuss positive
CHMP opinion –

InterMune, Inc. (Nasdaq: ITMN) today announced additions to its senior
leadership team to prepare for the commercialization of Esbriet(TM)
(pirfenidone) in Europe. InterMune's Marketing Authorization Application
(MAA) for Esbriet received a positive CHMP …. Original article on Gaea Times at  : InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet(TM) (Pirfenidone) in Europe.

Teysuno(TM) (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer

Recommendation Marks Taiho's First Regulatory Milestone Outside of Japan and Asia

TOKYO, December 17, 2010 – Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka Holdings
Co., Ltd., announced today that the Committee for Medicinal Products for
Human Use (CHMP), a division of the European Medicines Agency (EMA), has
issued an opinion recommending approval of Teysuno(TM) (S-1), a …. Original article on Gaea Times at  : Teysuno(TM) (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer.

Phadia Allergy and Autoimmunity Products Commercially Approved in India

UPPSALA, Sweden, December 20, 2010 – Import, sales and distribution of Phadia's allergy, asthma and
autoimmunity diagnostics products, including ImmunoCAP and EliA, have been
commercially approved by the Indian authorities.

(Logo:
www.newscom.com/cgi-bin/prnh/20101208/425503 )

Following official approval, Phadia will begin marketing a broad
portfolio of diagnostic products to major commercial laboratories, hospitals
and …. Source article  : Phadia Allergy and Autoimmunity Products Commercially Approved in India.

BSI: Guidance is Key to Improve Dementia Care

LONDON, December 20, 2010 – Dementia is a critical health concern, but are the current care services
able to offer appropriate support? Only a few days ago, the review by the
Royal College of Psychiatrists found many dementia patients were not getting
the support on nutrition and mental health that they should. The need for
improved care is … Read more >>>.

HeartSine Technologies Wins 2010 Aisling Award for Outstanding Achievement in Business

Distinction goes to the firm that made most significant contribution to community

BELFAST, Northern Ireland, December 20, 2010 – HeartSine Technologies received the Outstanding Achievement in Business
Award at the 14th annual Aisling Awards ceremony, November 25th, in Belfast,
Northern Ireland. The award honors an exemplary company who has made
significant contributions to Belfast and surrounding communities.
… Read this article on Gaea Times at : HeartSine Technologies Wins 2010 Aisling Award for Outstanding Achievement in Business.

Fourth Annual Probiotics Grant Continues to Fuel Growth In Research

Young Investigators invited to apply -
ALEXANDRIA, Virginia, December 20, 2010 – Today, the Global Probiotics Council (GPC), a committee formed by Danone
and YAKULT HONSHA CO., LTD., announced the launch of the fourth annual Young
Investigator Grant for Probiotics Research (YIGPRO). This grant provides two
awards, each in the amount of $50,000, to rising young stars. This … Read more : Fourth Annual Probiotics Grant Continues to Fuel Growth In Research.

Merck Serono and Philochem Enter Into Research Agreement in Fertility

GENEVA, December 21, 2010 – Merck Serono, the pharmaceutical division of Merck KGaA,
Darmstadt, Germany, today announced a strategic agreement with Philochem AG,
Switzerland, the research unit of Philogen S.p.A., Italy. Under the terms of
the agreement, Philochem will supply specific monoclonal antibodies to Merck
Serono, to be used in the search for molecular biomarkers of oocyte and
embryo … Read this article on Gaea Times at : Merck Serono and Philochem Enter Into Research Agreement in Fertility.

Israel’s iPad Doctors: Innovative Israeli Hospital Mayanei Hayeshua in Bnei Brak is First to Equip its Medical Staff With the Latest iPad Computers

BNEI BRAK, Israel, December 21, 2010 – Mayanei Hayeshua Medical Center (MYMC) is the first Israeli hospital to
give iPad technology to its doctors, for use both on and off-site. Medical
staff can now check patient records, test results, hi-resolution X-rays and
CT scans, report on patient progress and plan ongoing treatment using the
latest hand-held computers.

…. Source article  : Israel's iPad Doctors: Innovative Israeli Hospital Mayanei Hayeshua in Bnei Brak is First to Equip its Medical Staff With the Latest iPad Computers.

Gold Nanomedicine Clinical Trial Delivers Promising Results

Novel Approach in Cancer Therapy at the Forefront of Gold-Based Medical Applications

LONDON, December 21, 2010 – The World Gold Council (WGC) is delighted with the successful phase 1
clinical trial of a unique nanomedicine that uses nanoparticles of gold as
the core of a delivery system for tumour targeted drug delivery. The
research, published in the current …. Source  : Gold Nanomedicine Clinical Trial Delivers Promising Results.

Elevance Renewable Sciences Raises $100 Million in Series C Financing

BOLINGBROOK, Illinois, December 21, 2010 – Elevance Renewable Sciences, Inc. announced today that it has raised $100
million in its Series C financing round. Elevance produces high performance
ingredients for use in personal care products, detergents, lubricants and
other specialty chemicals and fuel markets from renewable feedstocks. Naxos
Capital Partners led the round with additional new investors, including …. Source  : Gaea News Network.

Bradesco Aims for 20 Million New Customers in the Coming Years

SAO PAULO, December 21, 2010 – The following was released today by Bradesco Seguros (NYSE: BBD)

Strategy

Bradesco Seguros, the largest insurance group in Latin America with
approximately 36 million policyholders and annual revenue around US$ 14
billion, hopes to add 20 million new clients, leveraged primarily on the
strength of … Read more : Bradesco Aims for 20 Million New Customers in the Coming Years.

Helsinn Birex Pharmaceuticals Limited has Been Assigned Certain International Rights to Klean-Prep(R) by Helix BioPharma Corp.

LUGANO, Switzerland, December 22, 2010 – Helsinn Birex Pharmaceuticals Ltd, has been assigned world-wide rights,
title and interest in Klean-Prep(R), excluding Canada, and an exclusive
license for the U.S.

Helsinn, a pharmaceutical group based in Lugano, Switzerland today
announced that it has entered into an agreement and has been assigned by
Helix BioPharma Corp., world-wide …. Read the original article  : Helsinn Birex Pharmaceuticals Limited has Been Assigned Certain International Rights to Klean-Prep(R) by Helix BioPharma Corp..

Sri Sri Ravi Shankar Endorses Divine Wellness.com

KANPUR, India, December 22, 2010 – Having already established its credibility and authority in the domain of
holistic Indian health and wellness services internationally, Divine Wellness
has added yet another feather to its cap by earning appreciation from none
other than the revered Sri Sri Ravi Shankar (The Art of Living) this month.
www.divinewellness.com/Details-news.aspx?ID=329 (click to view)

…. Original source  : Sri Sri Ravi Shankar Endorses Divine Wellness.com.

IV Russian-Indian Forum on Trade and Investments

ST. PETERSBURG, Russia, December 22, 2010 – The IV Russian-Indian Forum on Trade and Investments was held on December
20, 2010.

Particular attention was paid to developing partnership in
information and communication technology, pharmaceuticals and life sciences,
energy and energy resources, chemical products and fertilizers. A roundtable
meeting was held on cooperation in industrial manufacturing, …. Original article on Gaea Times at  : IV Russian-Indian Forum on Trade and Investments.